EXPEDITION 3
EXPEDITION 3 tested solanezumab in mild Alzheimer’s disease and did not meet its primary endpoint. It is included as a negative amyloid-antibody result.
Overview
A large phase 3 trial of an amyloid antibody that did not slow clinical decline as designed. Listed so the pipeline layer includes failures, not only approvals.
- Numbers are not recorded here for this endpoint. Solanezumab: Did not meet the primary endpoint; Placebo.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: Mild Alzheimer’s disease. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Similar pages
not linked directly; found by shared links- TreatmentRemternetug
Shares Eli Lilly, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TrialTRAILBLAZER-ALZ 2
Shares Eli Lilly, Alzheimer’s disease and the tag dementia-atlas.
- TrialENGAGE
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentAducanumab
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- TreatmentDonanemab
Shares Eli Lilly, Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- IdeaBlood test before PET or lumbar puncture
Shares Anti-amyloid medicines, Alzheimer’s disease and the tag dementia-atlas.
- PersonAlois Alzheimer
Shares Alzheimer’s disease and the tag dementia-atlas.
- TreatmentBrexpiprazole
Shares Alzheimer’s disease and the tag dementia-atlas.